XELJANZ 11mg prolonged-release tablets provide RA patients a once-daily dosing option
Pfizer Healthcare Ireland has today announced the availability of XELJANZ® (tofacitinib citrate) 11mg prolonged-release tablets for the once-daily treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate in patients who have had an inadequate response or intolerance to methotrexate or other DMARDs.
Commenting on the announcement, Michael Stewart, I&I Lead Ireland, Pfizer Healthcare Ireland said; “Pfizer continues to be an innovator in inflammation and immunology. The introduction of XELJANZ 11mg once daily tablets provides physicians with another treatment option for rheumatoid arthritis patients who may prefer an oral once-daily treatment. Xeljanz also has a close connection here in Ireland as it is manufactured in our Ringaskiddy site in Cork.”